Improving Scalability And Manufacturing Capacity

Due to the bespoke nature of autologous CAR-T manufacturing, facilities can only produce so many therapies at once. This creates a sort of bottleneck that results in treatment delays for patients. In this segment from the Cell & Gene Live! Event Modernizing CAR-T Manufacturing: Is Point Of Care The Future?, our panelists discuss the inherent challenges of cell therapy manufacturing and the need for innovation to improve manufacturing scale and capacity.